Parkinson's Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for the disease since 2019.
Related reading: Unraveling Parkinson's: The Power of Neuroimaging Biomarkers and Revolutionizing Drug Development for Parkinson's Disease by Using Imaging Biomarkers Analysis.
Reason #1: MRI Biomarkers as Regulatory-Ready Endpoints in PD Trials
Despite their clear scientific value, MRI biomarkers are still underused in Parkinson's disease clinical trials.
The FDA has released specific guidance to assist and support the use of imaging data in clinical trials as primary or component endpoints. This guidance acknowledges that imaging biomarkers can provide objective, reproducible, and quantifiable evidence of treatment effects — qualities that are difficult to achieve with traditional clinical rating scales. By incorporating FDA-endorsed imaging endpoints, Parkinson's trial sponsors can align their evidence packages with regulatory expectations and potentially accelerate the pathway to approval.
Reason #2: MRI Biomarkers for Parkinson's Patient Stratification and Recruitment
Parkinson's disease is a heterogeneous condition comprising diverse clinical phenotypes and atypical parkinsonian syndromes with overlapping features.
Evidence suggests that several MRI biomarkers have the ability to both distinguish between PD subtypes and predict response to therapy.
Any improvement in patient selection would inevitably enhance statistical power, meaning smaller sample sizes and lower long-term study costs.
Reason #3: In Vivo Disease Insights — What MRI Reveals That Clinical Scales Miss
In slowly progressing diseases like PD — where clinical manifestations are preceded by a prodromal phase — highly sensitive imaging biomarkers can detect subtle longitudinal changes that clinical scales may miss.
MRI biomarkers can reveal biological change earlier and more objectively than conventional clinical scales alone.
Reason #4: Scalable, Reusable MRI Data — Maximising ROI Across Multiple Parkinson's Studies
Parkinson's disease trials often collect MRI data primarily for safety monitoring, leaving a wealth of high-quality imaging data underanalysed.
As MRI acquisition protocols become increasingly standardised and AI-powered analysis tools mature, sponsors can retrospectively apply advanced analytical algorithms to previously collected datasets — extracting new biomarker insights without the cost of a new study.
This retrospective approach is especially valuable given the growing availability of large longitudinal imaging datasets and the rapidly improving capabilities of AI algorithms for tasks such as volumetric analysis, iron quantification, and white matter microstructure assessment.
For related examples, see retrospective analyses.
Reason #5: MRI Biomarkers as a Competitive Differentiator in Parkinson's Drug Development
The Michael J. Fox Foundation's Biomarker Advancement Programs include a dedicated Imaging Program that specifically targets imaging-based solutions to accelerate Parkinson's disease drug development.
MRI biomarkers can help sponsors generate richer datasets and more differentiated evidence packages in increasingly competitive development environments.
QMENTA provides a cloud-native imaging platform that addresses the operational challenges of multi-site MRI biomarker studies in Parkinson's disease: centralised data management with automated protocol adherence checking and quality control, a catalogue of validated AI imaging biomarker algorithms, regulatory-ready audit trails and documentation, and flexible integration with other imaging endpoints. The platform is designed to be deployable without site-level software installation, reducing the burden on clinical sites and accelerating study start-up timelines.
Frequently Asked Questions
Why are MRI biomarkers underused in Parkinson's disease clinical trials?
Despite their clear scientific value, MRI biomarkers are used as primary, secondary, or exploratory outcomes in only approximately 16% of active Parkinson's disease clinical trials. The underuse reflects several barriers: the analytical complexity of advanced MRI sequences, the logistical challenges of standardising data collection across multiple sites and scanner vendors, and the historical reliance on clinical scales such as UPDRS as the dominant outcome measures. As MRI acquisition protocols become more standardised and cloud-based imaging platforms reduce the logistical burden, MRI biomarkers are increasingly accessible for broader trial deployment.
What does FDA guidance say about imaging biomarkers as clinical trial endpoints?
The FDA has released specific guidance to assist and support the use of imaging data in clinical trials as primary or component endpoints. This guidance acknowledges that imaging biomarkers can provide objective, reproducible, and quantifiable evidence of treatment effects — qualities that are difficult to achieve with traditional clinical rating scales. By incorporating FDA-endorsed imaging endpoints, Parkinson's trial sponsors can align their evidence packages with regulatory expectations and potentially accelerate the pathway to approval.
How can MRI biomarkers improve patient stratification in Parkinson's disease trials?
Parkinson's disease is a heterogeneous condition comprising diverse clinical phenotypes and atypical parkinsonian syndromes with overlapping features. MRI biomarkers — including quantitative susceptibility mapping (QSM) for iron deposition in the substantia nigra, free-water diffusion tensor imaging (DTI) for white matter microstructure, and neuromelanin-sensitive MRI — can distinguish between PD subtypes and predict response to specific therapies. Improved patient stratification enhances statistical power, meaning trials can achieve meaningful results with smaller sample sizes and lower overall cost. Any reduction in the misclassification of patients entering a trial directly reduces the risk of Phase 2 to Phase 3 transition failure.
What is the Michael J. Fox Foundation's Imaging Program and why is it relevant?
The Michael J. Fox Foundation's Biomarker Advancement Programs include a dedicated Imaging Program that specifically targets imaging-based solutions to accelerate Parkinson's disease drug development. The program reflects the foundation's recognition that the limited transition of disease-modifying therapies from Phase 2 to Phase 3 may stem in part from an incomplete understanding of PD biology — a gap that in vivo imaging biomarkers are well-positioned to fill. The program's existence signals strong institutional and philanthropic support for imaging-first approaches in PD research, which is an encouraging indicator for sponsors considering MRI biomarker investment.
How can existing MRI data be repurposed to maximise study value in Parkinson's research?
Parkinson's disease trials often collect MRI data primarily for safety monitoring, leaving a wealth of high-quality imaging data underanalysed. As MRI acquisition protocols become increasingly standardised and AI-powered analysis tools mature, sponsors can retrospectively apply advanced analytical algorithms to previously collected datasets — extracting new biomarker insights without the cost of a new study. This retrospective approach is especially valuable given the growing availability of large longitudinal imaging datasets and the rapidly improving capabilities of AI algorithms for tasks such as volumetric analysis, iron quantification, and white matter microstructure assessment.
What infrastructure does QMENTA provide for MRI biomarker studies in Parkinson's disease?
QMENTA provides a cloud-native imaging platform that addresses the operational challenges of multi-site MRI biomarker studies in Parkinson's disease: centralised data management with automated protocol adherence checking and quality control, a catalogue of validated AI imaging biomarker algorithms (including those applicable to Parkinson's disease such as volumetric analysis and quantitative MRI tools), regulatory-ready audit trails and documentation, and flexible integration with other imaging endpoints. The platform is designed to be deployable without site-level software installation, reducing the burden on clinical sites and accelerating study start-up timelines.
Author: Evie Neylon, Neuroimaging Product Manager, QMENTA
